Back in 2010, the most interesting point Radient made while attempting to acquire Provista was:
"Provista has all of the rights and patents (some pending) and trademarks for several diagnostic technologies that we believe will strengthen and complement our business. These technologies include a diagnostic blood test for Alzheimers, Breast Cancer, dementia and other women’s cancers. We have a Confidentiality Agreement with Provista, which shall survive the expiration or termination of the LOI."
What works for Radient taking over Provista also works for Provista taking over Radient. DR-70 is a key component for a number of Provista cancer tests, and will strengthen Provista in their quest when they go public thru the Radient shell.
I also am warming up to the notion of acquiring AMBS as well, since the alzheimer/parkinson testing would be a natural fit for the ambitious Gartner.
